Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

AI-Driven IOL Prediction Using SS-OCT Biometry

23 de julio de 2026 actualizado por: The Hong Kong Polytechnic University

International Multicenter Evaluation of a Novel SS-OCT Biometer and Development of an AI-Driven Intraocular Lens Power Prediction Model

This prospective, multicenter, non-interventional observational study aims to evaluate the agreement between a novel swept-source optical coherence tomography (SS-OCT) biometer and the IOLMaster 700 for ocular biometric measurements and to develop and validate an artificial intelligence (AI)-driven intraocular lens (IOL) power prediction model.

The primary research questions are:

Does the novel SS-OCT biometer provide ocular biometric measurements that are comparable to those obtained using the IOLMaster 700? Can an AI-driven IOL power prediction model developed from multicenter biometric, imaging, surgical, and postoperative refractive data improve the accuracy of postoperative refractive prediction?

Adult patients with age-related cataract who are scheduled to undergo routine phacoemulsification with posterior chamber IOL implantation will be consecutively recruited from participating study centers. Participants will undergo routine preoperative clinical assessments together with additional non-contact biometric measurements using the novel SS-OCT biometer before cataract surgery. Cataract surgery and postoperative care will follow standard clinical practice and will not be influenced by the study. Postoperative refractive and visual outcomes at approximately one month after surgery will be collected for analysis. The AI model and research device measurements will be used for research purposes only and will not be used to guide clinical decision-making during the study.

Descripción general del estudio

Estado

Aún no reclutando

Condiciones

Intervención / Tratamiento

Tipo de estudio

De observación

Inscripción (Estimado)

2500

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

Ubicaciones de estudio

  • Australia
      • Adelaide, Australia
        • Royal Adelaide Hospital (tentative)
        • Contacto:
  • Hong Kong
      • Kowloon City, Hong Kong
        • Hong Kong Eye Hospital
        • Contacto:
  • Porcelana
    • Hebei
      • Wuhan, Hebei, Porcelana, 430032
        • Wuhan Purui Ophthalmology Hospital
        • Contacto:
          • zhimin Huang
          • Número de teléfono: 8615007176939
          • Correo electrónico: 625806284@qq.com

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

  • Adulto
  • Adulto Mayor

Acepta Voluntarios Saludables

No

Método de muestreo

Muestra no probabilística

Población de estudio

Adult patients with age-related cataract who are scheduled to undergo routine phacoemulsification and posterior chamber IOL implantation.

Descripción

Inclusion Criteria:

  1. Aged 18 years or above.
  2. Diagnosed with age-related cataract.
  3. Scheduled for routine phacoemulsification with posterior chamber intraocular lens implantation.
  4. Able to cooperate with preoperative ocular biometric measurements and postoperative assessments.
  5. Able to attend the planned 1-month postoperative follow-up visit.
  6. Able to understand the study information and provide written informed consent.

Exclusion Criteria:

  1. Ocular conditions that may significantly affect biometric measurements or postoperative refractive outcomes, including but not limited to severe corneal disease, severe ocular surface disease, advanced glaucoma, retinal detachment, severe maculopathy, significant optic nerve disease, or ocular trauma.
  2. History of previous intraocular surgery in the study eye, except minor superficial ocular procedures that are not expected to affect ocular biometry or refractive outcomes.
  3. Uncontrolled severe systemic disease that, in the opinion of the investigator or treating clinician, makes the patient unsuitable for routine cataract surgery or study participation.
  4. Cognitive impairment, severe mental disorder, or other condition that prevents the participant from understanding the study or providing valid informed consent.
  5. Poor cooperation that prevents reliable ocular biometric measurement or follow-up assessment.
  6. Current participation in another interventional clinical study that may affect the outcomes of this study.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

Cohortes e Intervenciones

Grupo / Cohorte
Intervención / Tratamiento
Cataract Surgical Participants
All adult participants diagnosed with age-related cataract scheduled for routine phacoemulsification and IOL implantation. All subjects receive parallel preoperative ocular biometry scans with IOLMaster 700 and a novel investigational SS-OCT biometer, followed by 1-month postoperative refractive follow-up. No clinical treatment assignment is altered for research purposes.
Dispositivo: IOLMaster 700
Commercially available swept-source OCT biometer for routine preoperative cataract ocular biometry, used for standard clinical care.
Dispositivo: Novel SS-OCT Biometer
Investigational prototype swept-source OCT biometer for research-only parallel measurement of ocular biometric parameters; results will not be used to determine clinical IOL power selection.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Agreement of ocular biometric parameters between Novel SS-OCT Biometer and IOLMaster 700
Periodo de tiempo: Preoperatively (single measurement visit before cataract surgery)
Bland-Altman 95% limits of agreement, mean difference, intraclass correlation coefficient (ICC) for six key biometric parameters: axial length, keratometry, anterior chamber depth, lens thickness, central corneal thickness, white-to-white diameter
Preoperatively (single measurement visit before cataract surgery)

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Measurement success rate of two biometers
Periodo de tiempo: Preoperatively
Percentage of valid, analyzable scans obtained from Novel SS-OCT Biometer vs IOLMaster 700
Preoperatively
Refractive prediction error of AI-driven IOL power model
Periodo de tiempo: 1 month postoperatively
Mean absolute error (MAE), median absolute error (MedAE), root mean square error (RMSE); proportion of eyes within ±0.5D / ±1.0D refractive prediction error
1 month postoperatively
AI model performance across multi-ethnic cohorts
Periodo de tiempo: 1 month postoperatively
Stratified refractive prediction error metrics among Chinese, Caucasian and other ethnic subgroups
1 month postoperatively
Incidence of transient ocular adverse events related to study biometric scans
Periodo de tiempo: From the preoperative measurement until completion of the 1-month postoperative follow-up
Proportion of participants with temporary dry eye, glare or foreign body sensation after repeated optical measurements
From the preoperative measurement until completion of the 1-month postoperative follow-up

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

The Hong Kong Polytechnic University

Investigadores

  • Investigador principal: Mingguang He, Prof., The Hong Kong Polytechnic University

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Estimado)

20 de agosto de 2026

Finalización primaria (Estimado)

20 de marzo de 2027

Finalización del estudio (Estimado)

31 de marzo de 2027

Fechas de registro del estudio

Enviado por primera vez

23 de julio de 2026

Primero enviado que cumplió con los criterios de control de calidad

23 de julio de 2026

Publicado por primera vez (Actual)

29 de julio de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

29 de julio de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

23 de julio de 2026

Última verificación

1 de julio de 2026

Más información

Términos relacionados con este estudio

Palabras clave

Términos MeSH relevantes adicionales

Otros números de identificación del estudio

  • HK-WH-OPH-202607

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Descripción del plan IPD

External sharing of individual participant data (IPD) is not planned. The raw ophthalmic imaging and clinical records are solely reserved for internal AI model training and analysis by the official multi-country research consortium. Participant informed consent does not authorize release of personal-level data to external researchers, and cross-border privacy laws as well as institutional IRB requirements restrict cross-site data distribution to third parties. In addition, the dataset carries proprietary intellectual property for AI medical device development, and external data access may cause unauthorized duplication of core algorithms.

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir